Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
作者信息
Kim Jin Yong
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Korea.
出版信息
J Korean Med Sci. 2020 Feb 24;35(7):e88. doi: 10.3346/jkms.2020.35.e88.
Abstract
摘要
相似文献
1
Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.致编辑的信：韩国首例导致新型冠状病毒肺炎三代传播的病例：洛匹那韦/利托那韦在定量逆转录聚合酶链反应监测下治疗新型冠状病毒肺炎的应用
J Korean Med Sci. 2020 Feb 24;35(7):e88. doi: 10.3346/jkms.2020.35.e88.
2
The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.作者回应：韩国首例导致新型冠状病毒肺炎三代传播病例：洛匹那韦/利托那韦用于治疗经定量逆转录聚合酶链反应监测的新型冠状病毒肺炎
J Korean Med Sci. 2020 Feb 24;35(7):e89. doi: 10.3346/jkms.2020.35.e89.
3
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.韩国第三代 COVID-19 感染传播者索引患者病例：应用洛匹那韦/利托那韦定量 RT-PCR 监测 COVID-19 感染肺炎的治疗。
J Korean Med Sci. 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79.
4
Darunavir does not prevent SARS-CoV-2 infection in HIV patients.达芦那韦不能预防HIV患者感染SARS-CoV-2。
Pharmacol Res. 2020 Jul;157:104826. doi: 10.1016/j.phrs.2020.104826. Epub 2020 Apr 20.
5
Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.抗病毒联合治疗在新冠病毒感染有症状患者中的安全性和有效性 - 一项随机对照试验（SEV-COVID 试验）：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 20;21(1):866. doi: 10.1186/s13063-020-04774-5.
6
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.与 SARS-CoV-2 感染住院非重症患者病毒持续排出相关因素及洛匹那韦/利托那韦治疗的影响。
Eur Respir J. 2020 Jul 16;56(1). doi: 10.1183/13993003.00799-2020. Print 2020 Jul.
7
Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir.洛匹那韦利托那韦治疗的 2 例 COVID-19 患者出现血清素综合征。
J Neurol Sci. 2020 Aug 15;415:116944. doi: 10.1016/j.jns.2020.116944. Epub 2020 May 27.
8
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
9
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.评价法维拉韦和干扰素与洛匹那韦/利托那韦和干扰素在 COVID-19 中度患者中的疗效和安全性：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 27;21(1):886. doi: 10.1186/s13063-020-04747-8.
10
Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.氯喹与洛匹那韦/利托那韦治疗轻症/普通 COVID-19 感染的疗效：一项前瞻性、开放标签、多中心、随机对照临床研究。
Trials. 2020 Jul 8;21(1):622. doi: 10.1186/s13063-020-04478-w.
引用本文的文献
1
Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.舍曲林是一种有效的针对刺突蛋白的 SARS-CoV-2 进入抑制剂。
J Virol. 2022 Dec 21;96(24):e0124522. doi: 10.1128/jvi.01245-22. Epub 2022 Dec 5.
2
A Narrative Review of Existing Options for COVID-19-Specific Treatments.关于 COVID-19 特异性治疗现有选择的叙述性综述。
Adv Virol. 2021 Nov 12;2021:8554192. doi: 10.1155/2021/8554192. eCollection 2021.
3
The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery.伊拉克库尔德地区政府（KRG）控制新冠疫情的策略：识别、流行病学、传播、治疗及康复
Int J Surg Open. 2020;25:41-46. doi: 10.1016/j.ijso.2020.06.006. Epub 2020 Jun 30.
4
Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome.迈向针对与衰老和代谢综合征相关的 COVID-19 的预防和治疗策略的目标。
Cells. 2021 Jun 6;10(6):1412. doi: 10.3390/cells10061412.
5
Delay-Adjusted Age-Specific COVID-19 Case Fatality Rates in a High Testing Setting: South Korea, February 2020 to February 2021.高检测环境下调整年龄别延迟的 COVID-19 病死率：韩国，2020 年 2 月至 2021 年 2 月。
Int J Environ Res Public Health. 2021 May 11;18(10):5053. doi: 10.3390/ijerph18105053.
6
Proteomic investigation reveals dominant alterations of neutrophil degranulation and mRNA translation pathways in patients with COVID-19.蛋白质组学研究揭示了新冠肺炎患者中性粒细胞脱颗粒和mRNA翻译途径的主要改变。
iScience. 2021 Mar 19;24(3):102135. doi: 10.1016/j.isci.2021.102135. Epub 2021 Feb 4.
7
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.SARS-CoV-2：感染引起的免疫反应和疫苗及治疗的发展。
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
8
Current status of COVID-19 pandemic; characteristics, diagnosis, prevention, and treatment.2019冠状病毒病大流行的现状；特征、诊断、预防及治疗
J Res Med Sci. 2020 Nov 3;25:101. doi: 10.4103/jrms.JRMS_476_20. eCollection 2020.
9
Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.计算药物发现和再利用治疗 COVID-19：系统评价。
Bioorg Chem. 2021 Jan;106:104490. doi: 10.1016/j.bioorg.2020.104490. Epub 2020 Nov 19.
10
Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.新型冠状病毒感染治疗的新视角：当前临床试验概述。
Int J Biol Macromol. 2020 Dec 15;165(Pt A):18-43. doi: 10.1016/j.ijbiomac.2020.09.204. Epub 2020 Sep 28.
本文引用的文献
1
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).2019新型冠状病毒（2019-nCoV）的治疗选择。
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
2
Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.韩国第三代 COVID-19 感染传播者索引患者病例：应用洛匹那韦/利托那韦定量 RT-PCR 监测 COVID-19 感染肺炎的治疗。
J Korean Med Sci. 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79.
3
The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures.韩国首例中国武汉输入性 2019 新型冠状病毒肺炎病例：感染防控措施启示。
J Korean Med Sci. 2020 Feb 10;35(5):e61. doi: 10.3346/jkms.2020.35.e61.
4
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
5
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.洛匹那韦/利托那韦在严重急性呼吸综合征治疗中的作用：初步病毒学及临床研究结果
Thorax. 2004 Mar;59(3):252-6. doi: 10.1136/thorax.2003.012658.
6
Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.洛匹那韦/利托那韦治疗严重急性呼吸综合征：一项多中心回顾性匹配队列研究。
Hong Kong Med J. 2003 Dec;9(6):399-406.
Zotero 插件